Experimental drug targets rare fat Disorder's metabolic woes
NCT ID NCT05088460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a drug called REGN4461 (mibavademab) in 20 people with familial partial lipodystrophy, a rare condition causing abnormal fat distribution and metabolic problems. The study aimed to see if the drug could lower high triglycerides and improve blood sugar control. However, the trial was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN4461 (mibavademab)
What this could lead to
If it works, this could point toward a treatment to control metabolic problems like high triglycerides and blood sugar in people with familial partial lipodystrophy.
What could go wrong
The trial was terminated early, so results are limited. It was a small phase 2 study with only 20 participants, so findings may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo
Santiago de Compostela, Galicia, 15706, Spain
-
Ege University Faculty of Medicine
Izmir, Bornova, 35100, Turkey (Türkiye)
-
Excel Medical Clinical Trials - A Flourish Research Site
Boca Raton, Florida, 33434, United States
-
ICAN, Institute of Cardiometabolism and Nutrition
Paris, 75013, France
-
National Institute of Health
Bethesda, Maryland, 20892, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States